9,848 Shares of Cencora, Inc. $COR Purchased by Vise Technologies Inc.

Vise Technologies Inc. acquired a new stake in Cencora, Inc. (NYSE:COR) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 9,848 shares of the company’s stock, valued at approximately $2,957,000.

A number of other large investors also recently bought and sold shares of COR. Elevation Wealth Partners LLC raised its stake in shares of Cencora by 506.2% in the 2nd quarter. Elevation Wealth Partners LLC now owns 97 shares of the company’s stock valued at $27,000 after acquiring an additional 81 shares during the period. Bell Investment Advisors Inc acquired a new position in shares of Cencora in the 2nd quarter worth approximately $28,000. Caitlin John LLC purchased a new position in shares of Cencora during the 2nd quarter worth approximately $28,000. Cassaday & Co Wealth Management LLC purchased a new position in shares of Cencora during the 1st quarter worth approximately $35,000. Finally, Lynch Investment Planning LLC purchased a new position in shares of Cencora during the 3rd quarter worth approximately $39,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Elizabeth Campbell sold 11,300 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $324.12, for a total value of $3,662,556.00. Following the sale, the executive vice president owned 19,455 shares of the company’s stock, valued at $6,305,754.60. This trade represents a 36.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.38% of the stock is currently owned by company insiders.

Trending Headlines about Cencora

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Fiscal Q4 adjusted EPS of $4.66 beat the $4.58 consensus, while revenue of $88.35 billion topped estimates of $87.95 billion and rose 5.5% year over year. Cencora also reported higher earnings than a year earlier. Article: Cencora Q4 Earnings & Revenues Beat on Specialty Growth, Margins Expand
• Positive Sentiment: The company forecast fiscal 2027 EPS of $19.40–$19.75, with specialty growth supporting its outlook. The guidance gives investors an indication of continued earnings growth. Article: Cencora outlines fiscal 2027 EPS outlook
• Positive Sentiment: Cencora raised its quarterly dividend 10%, from $0.60 to $0.66 per share, signaling increased cash returns to shareholders. Company dividend information
• Neutral Sentiment: Cencora is reorganizing its reporting structure to improve focus and visibility. The change may help execution, though the new structure itself does not establish a near-term financial benefit. Article: Cencora announces new organizational and reporting structure
• Neutral Sentiment: Management’s earnings-call discussion was broadly positive but included mention of headwinds; the provided coverage does not detail their size or likely effect on results. Article: Cencora earnings call highlights specialty growth and headwinds

Cencora Trading Up 4.0%

NYSE:COR opened at $354.20 on Thursday. The firm has a market cap of $67.59 billion, a PE ratio of 26.31, a price-to-earnings-growth ratio of 1.74 and a beta of 0.58. The stock has a fifty day moving average price of $324.60 and a 200 day moving average price of $317.44. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54. The company has a current ratio of 0.93, a quick ratio of 0.58 and a debt-to-equity ratio of 3.53.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $4.66 earnings per share for the quarter, topping the consensus estimate of $4.58 by $0.08. The company had revenue of $88.35 billion for the quarter, compared to the consensus estimate of $87.95 billion. Cencora had a return on equity of 125.45% and a net margin of 0.79%. Cencora’s revenue was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.84 EPS. Sell-side analysts anticipate that Cencora, Inc. will post 17.88 earnings per share for the current fiscal year.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 30th. Investors of record on Friday, November 13th will be paid a dividend of $0.66 per share. The ex-dividend date is Friday, November 13th. This is a positive change from Cencora’s previous quarterly dividend of $0.60. This represents a $2.64 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s payout ratio is currently 17.83%.

Wall Street Analyst Weigh In

Several analysts recently weighed in on COR shares. JPMorgan Chase & Co. lifted their target price on shares of Cencora from $382.00 to $390.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Bank of America upped their price target on Cencora from $285.00 to $310.00 in a research note on Tuesday, July 21st. Citigroup restated a “buy” rating on shares of Cencora in a research report on Thursday, August 6th. Wall Street Zen raised Cencora from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Robert W. Baird boosted their price objective on Cencora from $373.00 to $375.00 and gave the company an “outperform” rating in a report on Thursday, October 22nd. Fourteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and an average target price of $368.38.

Cencora Company Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical sourcing and distribution company. It provides branded, generic and specialty pharmaceuticals, over-the-counter products and related health care supplies to pharmacies, hospitals, health systems, physician practices and other health care providers.

The company also offers services to pharmaceutical and biotechnology manufacturers, including logistics, commercialization support, market access, consulting, clinical trial support and patient assistance programs.